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Background: Recent studies suggest that neurokinin B and its receptor, neurokinin 3 receptor, have an essential
role in the regulation of gonadotropin-releasing hormone and luteinizing hormone (LH) release in several
mammalian species. As the first trial, this pilot study reports the effect of intravenous treatment with senktide, a
selective agonist of neurokinin 3 receptor, on LH secretion, follicular development in female goats that were
clinically diagnosed with anestrus.
Findings: Anestrous goats were intravenously administered 200 nmol senktide at 4-h intervals for 24 h. Most of
them examined (5/6 cases) showed a pulsatile increase in LH secretion after each injection of senktide, whereas
the remaining one case showed a surge-like increase of LH secretion. Ovulation was confirmed in 5/6 cases at the
range of 48–96 h after the beginning of treatment.
Conclusions: This pilot study demonstrated that intravenous treatment with senktide has therapeutic action in goats
with anestrus by inducing LH release, which could promote follicular development and ovulation.
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Introduction
Neurokinin B (NKB) is a member of the tachykinin family
of peptides. Recent studies have revealed that hypo-
thalamic signaling of NKB and its receptor, neurokinin 3
receptor (NK3R), has an important role in the regulation
of gonadotropin-releasing hormone (GnRH) neurosecre-
tion in mammalian species [1]. Loss-of-function muta-
tions of Tac3 and Tacr3, which encode NKB and NK3R,
respectively, have been identified in patients with hypogo-
nadotropic hypogonadism [2]. Subsequently, research using
animal models found that exogenous administration of NKB
stimulates neural oscillation governing pulsatile GnRH [3]
and luteinizing hormone (LH) secretion [4,5]. NKB has
affinity for other tachykinin receptors, even though mar-
ginal, which might compromise the interpretation of the* Correspondence: tomomit@cc.tuat.ac.jp
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[6]. To overcome this problem, senktide was developed
as a highly selective and potent agonist of NK3R [7], and
currently available only for experimental use. Along with
investigating the physiological role of NKB/NK3R system
in various stages of the reproductive process, attention is
now focused on the therapeutic use of NK3R agonists, e.g.
senktide, to accelerate or improve gonadal activity in
humans as well as domestic animals [8].
Anestrus is a major component of postpartum infertility
in domestic animals including dairy cows [9], which
extends calving interval and leads great economic loss for
farmers. Particularly in high-yielding dairy cows, occur-
rence of anestrus is often associated with nutritional defi-
ciency in early lactation period. The condition of anestrus
is characterized by the lack of ovarian cycles or gonadal
activity with repeated turnover of follicles without ovula-
tion. The existing follicles are incapable of producing suffi-
cient estradiol-17β (E2) to induce ovulation, owing to thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 LH and E2 concentrations from −2 to 6 h after the
beginning of senktide treatment. Arrows indicate the time when
200 nmol senktide was administered intravenously. *: Different
significantly (P <0.05) compared with the pretreatment (0 h) value.
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crine background of anestrus into consideration, anestrous
animals are relevant subjects for investigating the thera-
peutic action of NKB on ovarian dysfunction through the
stimulation of GnRH/LH secretion.
Shiba goats are non-seasonal breeders under natural
daylight conditions in Japan, and are used as experimen-
tal and clinical models for the investigation of reproduct-
ive functions in domestic ruminants. Anestrus is also
observed in this species, although the incidence is very
low under normal management conditions. In this pilot
study, we examined the effect of intravenous treatment
with senktide on LH secretion and follicular develop-
ment in anestrous female goats.
Methods
The study protocol was approved by the University
Committee for Use and Care of Animals at Tokyo
University of Agriculture and Technology (#22-67). Five
Shiba goats (2.4 ± 0.5 years of age; 21.8 ± 3.6 kg of body
weight) that were clinically diagnosed with anestrus were
subjected to the study. The goats and other herd-mates
were maintained in an outdoor paddock and fed a main-
tenance diet based on alfalfa hay cubes twice daily, under
group feeding conditions. The five goats had no estrus
signs more than 30 days after the last appearance of
estrus. After the expected day of estrus (20 or 21 days
after ovulation), no functional corpus lutea and only antral
follicles were detected by ovarian ultrasonography
(7.5 MHz linear probe, HLS-375 M, Honda Electronics
Co., Ltd., Aichi, Japan) and the progesterone concen-
tration in plasma was lower than 1 ng/ml. They received
senktide on 48.2 ± 16.8 days after the last appearance
of estrus.
On the day of the experiment, a catheter was inserted
into the jugular vein. The goats were treated seven times
with 200 nmol senktide in 5 ml of saline containing
0.25% dimethyl sulfoxide at 4-h intervals, beginning at
1100 h (designated as 0 h). The senktide solution was
injected slowly over 5 minutes via the jugular catheter.
The dose of senktide was determined according to a
previous study [10] to induce pulsatile LH secretion in
ovariectomized Shiba goats. Blood samples (1.5 ml) were
collected in heparinized tubes through the catheter at
10-min intervals from −2 to 4 h, at 4-h intervals from 4
to 24 h, at 6-h intervals from 24 to 48 h after the begin-
ning of treatment, and thereafter at 24-h intervals up to
120 h. Plasma was separated and assayed for LH, E2 and
progesterone [11]. Ovarian ultrasonography was perfor-
med 2 days before the treatment, just before the treatment
(between 0700 and 0800 h on the experiment day) and
then daily until 5 days after treatment. All follicles and
corpus lutea that were larger than 2 mm in diameter
were recorded. All measured values are presented asmeans ± SD. Differences between means were evaluated
by analysis of variance followed by Dunnett’s multiple
comparison test or paired t-test. Differences with P <0.05
were considered to be significant.
Results
Almost all cases (5/6, except for no.9) showed a pulsatile
increase in LH concentration in response to each senk-
tide treatment; the LH concentration increased rapidly
and reached a peak at 10–20 min after each injection.
In these five goats, LH concentrations at 10–20 min
after the first injection and at 10–30 min after the
second injection were significantly higher (P <0.05) than
the pretreatment level (Figure 1). As for E2, the mean
concentration during the pre-treatment 2 h were 5.9 ±
0.9 pg/ml. The E2 concentrations fluctuated and no signi-
ficant change was observed in the hourly profiles for 6 h
after the senktide treatment.
Profiles of LH and E2, occurrence of estrus and ovula-
tion in all cases are shown in Figure 2. Estrus and ovula-
tion were observed 2/6 and 5/6 cases, respectively. In the
four of five cases that showed a pulsatile increase of LH
release, ovulation occurred in response to senktide treat-
ment at 72 (no.17) or 96 h (no.12-2, no.13 and no.15) after
the beginning of treatment. Two cases (no.13 and no.15)
showed standing estrus one to two days before the day of
ovulation. E2 level showed a gradual increase through the
24-h repetitive injections. The peak of E2 concentration,
which was detected at 20–48 h after the beginning of
treatment, was preceded or approximately coincided with
the peak of LH.
Only one case (no.12-1) failed to ovulate, although a
pulsatile increase in LH concentration was clearly obser-
ved in response to each injection of senktide. The E2
concentration was higher than 5 pg/ml around the time of
first injection. However, it decreased to the basal level by
6 h after the beginning of treatment and was maintained
lower than 5 pg/ml throughout the experiment.
Figure 2 Profiles of LH and E2, occurrence of estrus and ovulation in all six goats examined. Plasma LH and E2 concentrations in the samples
collected every 4 h from 0 to 24 h, every 6 h from 24 to 48 h, and then every 24 h until 120 h. Arrows indicate the time when 200 nmol senktide was
administered intravenously. Es: Estrus behavior was detected by visual observation. Ov: Ovulation was confirmed by ovarian ultrasonography.
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other five goats. Mean concentrations of LH and E2 dur-
ing the pre-treatment 2 h in this goat was 4.0 ± 2.5 ng/ml
and 8.1 ± 4.7 pg/ml, respectively. A surge-like increase in
LH concentration was observed, with a peak of 56.1 ng/ml
at 3 h after the first injection. The E2 concentration
showed a concomitant increase with the increase of LH,
followed by a gradual decrease by the time of ovulation
(at 48 h after the beginning of treatment).
Goats that ovulated upon the senktide treatment had
2–4 follicles with a diameter larger than 3 mm (mean,
4.0 ± 0.6 mm) on the day of treatment. Finally, 1–4 ovu-
latory follicles per goat grew after the treatment, and the
mean maximal diameter of them was 4.8 ± 0.6 mm. The
goat that failed to ovulate (no.12-2) had only one follicle
with a smaller diameter of 2.7 mm on the day of
treatment, although three additional small follicles were
detected 24 h later.
Additional monitoring of ovarian dynamics and blood
progesterone concentrations in the ovulated five goats
indicated that premature luteal regression occurred (data
not shown) and estrus was observed at 5–18 days after
the senktide-induced ovulation.
Discussion
The present study showed the stimulatory action of NKB
on the LH secretion in almost all goats with anestrous
symptom, in which there was a pulsatile increase in LH
concentration in response to each senktide treatment.
Recently, it has been revealed that a specific subset ofneurons in the arcuate nucleus (ARC) in the hypotha-
lamus, colocalized three neuropeptides, kisspeptin, NKB
and dynorphin [12,13], and is a likely candidate for the
intrinsic GnRH pulse generator. Accumulating evidence
suggests that the action of NKB or its analog occurs
within the ARC through regulation of the release of
kisspeptin [3,4]. An in vitro study using cell-attached re-
cording method showed that both NKB and senktide have
a potent stimulatory action on the firing of kisspeptin
neurons derived from the ARC region of the mouse
hypothalamus [14]. In ovariectomized goats, GnRH pulse
generator activity at the ARC kisspeptin neurons, which
was monitored by recording the multiple-unit activity
in the hypothalamus, was stimulated after the intra-
venous injection of senktide [10]. It is suggested that
small-amplitude release of LH (pulsatile LH secretion)
is induced by the stimulatory action of NKB on the
hypothalamic GnRH pulse generating system.
The present study is the first trial to evaluate the use
of NKB for the treatment of anestrus in goats. The ob-
tained findings are limited because there was no untreated
control group. In addition, the exact reasons for anestrus
remain unclear, but it is likely that insufficient nutrition
intake or other related factors such as stress might be
attributed to the incidence of anestrus, as has been experi-
mentally demonstrated in feed-restricted animals [15,16].
Consequently, most cases showed a therapeutic outcome;
there was a gradual increase in E2 secretion followed by
ovulation after the repetitive injections of senktide, at 4-h
intervals for 24 h. However, the treatment was insufficient
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in spite of the increased LH stimulation caused by senk-
tide treatment. One possible explanation for this is that
the failure of follicular development and/or ovulation
might be associated with the status of ovarian follicles
during senktide treatment. According to ultrasonographic
observation of ovaries during the estrous cycle in this spe-
cies [17], ovulatory follicles appear from 5 days before
ovulation and then grow to about 5 to 6 mm in diameter
in parallel with the increase in the plasma E2 concen-
tration. In addition to the fact that the anovulated goat
(no.12) had only one follicle sized 2.7 mm in diam-
eter on the day of treatment, the constantly low level of
E2 (<5 pg/ml) also indicates the absence of steroidogeni-
cally active follicle(s) that can respond to LH stimulation.
For optimal treatment of inactive ovary, the timing, dur-
ation and route of treatment seem to require adaptation
according to the follicular and endocrine conditions.
In one goat (no.9), a prominent increase in LH con-
centration close to those observed during the preovula-
tory LH surge was observed following the first injection
of senktide. A similar observation was reported from a
study by Billings et al. [5], in which a surge-like increase
in LH occurred after the treatment of senktide into the
third ventricle in ewes during the follicular phase but
not during the luteal phase. Although there may be
limits to this pilot study as it is based one case, it seems
likely that intravenous injection of senktide in a steroid
milieu similar to that present during the follicular phase
of the cycle can generate a preovulatory GnRH/LH surge,
as a trigger of ovulation.
In conclusion, the present pilot study showed that
intravenous treatment with senktide can stimulate LH
secretion in anestrous goats, suggesting the potential value
of NKB application in the treatment of reproductive disor-
ders. The increased release of LH resulted in ovulation
in most cases, except for one goat. This different out-
come might be associated with the developmental and
steroidogenic status of ovarian follicles during senktide
treatment.
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